HomeNews & TopicsResearchIllicit fentanyl, stimulants detected in majority of overdose deaths in BC

Illicit fentanyl, stimulants detected in majority of overdose deaths in BC

Published on

Nonprescribed fentanyl and stimulants were the primary contributors to overdose mortality, while few people had prescribed opioids in their systems, according to new toxicology research in CMAJ (Canadian Medical Association Journal)

“With health professional organizations introducing guidelines to reduce prescribing of opioids and other controlled substances, understanding the relative contribution of prescribed substances and illicitly obtained substances to overdose deaths is key to developing effective programs to reduce overdose mortality,” writes Dr. Alexis Crabtree, BC Centre for Disease Control and the University of British Columbia, with coauthors.

The postmortem study looked at deaths from drug overdoses identified by the BC Coroners Service between 2015 and 2017 with 1 or more illicit drugs. The deaths were linked to the person’s prescription medication history in British Columbia’s PharmaNet database. Of the total 2872 deaths, toxicology results were available for 1789 deaths, in which the majority (85.5%) had 1 or more opioids present. However, only 8.7% of individuals had taken prescribed opioids, and methadone and buprenorphine, used in opioid agonist therapy, were rarely detected in postmortem toxicology.

Of the deaths linked to nonprescribed opioids, fentanyl or fentanyl analogues were found in 79% of cases. Stimulants were found in 71% of deaths, almost all nonprescribed. Of the deaths in which benzodiazepines were detected, 63% had not been prescribed.

Death rates from illicit drugs increased more than fourfold between 2014 and 2018, which has been attributed to the contamination of the illicit drug supply. Over the past 5 years, British Columbia has had the highest rates of deaths from illicit drug use in Canada.

“[P]rescribing policies are insufficient to address the current overdose crisis in Canada and additional strategies are needed,” write the authors. “Physicians should be encouraged to practise patient-centred opioid prescribing.”

They suggest removing barriers to medically supervised opioid agonist therapy to provide a safer alternative to illegal drugs and supporting harm reduction organizations to provide care to people using nonprescribed medications.

In a related commentary, Dr. Mark Tyndall, School of Population and Public Health, University of British Columbia, Vancouver, BC, writes, “In the last 5 years, the major responses to the overdose crisis have been to reverse overdoses through harm reduction programs, build a better addiction care system, and create better housing and social services. Although these may be important actions and aspirations in the long term, they will not address the current emergency. Unless there is a radical change in our approach to the epidemic, overdose deaths will continue unabated. It is time to scale up safe supply and decriminalize drug use.”

“Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada” is published August 24, 2020.

Latest articles

The Cost of Silence: Why Black Youth Mental Health Can’t Wait

When we talk about mental health in Canada, the general numbers often hide a...

Iron deficiency anemia – demystifying a common, treatable and preventable public health problem

Over 830,000 Canadians have iron deficiency anemia (IDA),1 the most common cause of anemia.2...

Women living with Parkinson’s are overlooked and under-researched

Nearly half of Parkinson’s diagnoses are women, yet their care, support and research is...

Antibiotic resistance in Canada: What you can do

It’s normal to want quick relief when you’re sick fighting an infection. Antibiotics seem...

More like this

A new home for Canada’s largest Cancer Research Tumour Bank

Decades of cancer research — and thousands of patient tumour samples — now have...

Equity-focused study on immigrant kidney disease risk

HN Summary • A new SHN-led study published in BMJ Open reveals significant disparities in...

Shorter duration of antimicrobial therapy in common infections

HN Summary • Growing evidence shows that shorter courses of antibiotics are just as effective...

Global clinical trial exploring potential treatment for sickle cell disease

HN Summary • SHN is leading a global clinical trial testing tebapivat, an investigational oral...

Lithium study yields insights in the fight against HIV

Study in human cells finds low-cost drug keeps virus dormant through an unexpected pathway,...

Gene mutation in blood-forming cells may improve cancer immunotherapy results

Researchers at UHN’s Princess Margaret Cancer Centre have found that inactivation of the TET2...